Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474132 | 0.89 | ALDH1A1 (0.53) | NR1H4HDAC1L3MBTL1EPHX2GRM2 | |
| SCHEMBL30910306 | 0.87 | NR1H4 (0.48) | NR1H4HDAC1L3MBTL1EPHX2GRM2 | |
| SCHEMBL1205128 | 0.87 | NR1H4 (0.48) | NR1H4HDAC1L3MBTL1EPHX2GRM2 | |
| SCHEMBL7407052 | 0.86 | HDAC1 (0.48) | HDAC1L3MBTL1GRM2NAMPTCA1 | |
| SCHEMBL31019193 | 0.85 | NR1H4 (0.62) | NR1H4HDAC1L3MBTL1EPHX2GRM2 | |
| SCHEMBL1244785 | 0.85 | NR1H4 (0.61) | NR1H4HDAC1L3MBTL1EPHX2GRM2 | |
| SCHEMBL3897985 | 0.85 | NR1H4 (0.62) | NR1H4HDAC1L3MBTL1EPHX2GRM2 | |
| SCHEMBL16392318 | 0.85 | HDAC1 (0.47) | HDAC1L3MBTL1GRM2NAMPTCA1 | |
| SCHEMBL25256049 | 0.84 | NR1H4 (0.45) | NR1H4HDAC1L3MBTL1EPHX2GRM2 | |
| SCHEMBL16415430 | 0.84 | NR1H4 (0.45) | NR1H4HDAC1L3MBTL1EPHX2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-9834538-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170129873-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-9586929-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150291555-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2015-10-15 | — | — | US | disclosed |
| US-9096573-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| CN-104211684-A | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORP | 2014-12-17 | — | — | CN | disclosed |
| CN-101952272-B | 6-, 7-or 8-substituted quinazolinone derivatives, compositions containing the same, and methods of use thereof | CELGENE CORP | 2014-08-27 | — | — | CN | disclosed |
| EP-2200999-B1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20130289274-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2013-10-31 | — | — | US | disclosed |
| US-8492395-B2 | 7-substituted quinazolinone compounds and compositions comprising the same | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| CN-1863798-B | 2, 4-dioxo-3-quinazolinyl arylsulfonyl urea | PORTOLA PHARM INC | 2011-08-31 | — | — | CN | disclosed |
| CN-101952272-A | 6-, 7-or 8-substituted quinazolinone derivatives, compositions containing the same, and methods of use thereof | CELGENE CORP | 2011-01-19 | — | — | CN | disclosed |
| EP-2200999-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| WO-2009042177-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
| CN-1863798-A | 2, 4-dioxo-3-quinazolinyl arylsulfonyl urea | PORTOLA PHARM INC (US) | 2006-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289274-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | NR1H4 1369/4885HDAC1 1414/4885L3MBTL1 4608/4885 |
| US-20170129873-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | NR1H4 1369/4885HDAC1 1414/4885L3MBTL1 4608/4885 |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP2D6, CYP2B6 | NR1H4 1369/4885HDAC1 1414/4885L3MBTL1 4608/4885 |
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | NR1H4 1369/4885HDAC1 1414/4885L3MBTL1 4608/4885 |
| US-20150291555-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | NR1H4 1369/4885HDAC1 1414/4885L3MBTL1 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.